Healthcare public relations
Chamberlain Communications Group, one of the nation’s largest independent healthcare public relations specialists, has a particular talent for communicating urgent public health messages that educate and spur action among patients and physicians—even for established products in mature disease categories. In 2004, for example, Chamberlain developed the first-ever consumer public relations campaign for Novartis’s antihypertensive therapy Lotrel, creating a campaign—spearheaded by Hall of Fame quarterback Joe Montana—that clearly defined new blood pressure goals and provided patients with substantive, practical information on how to achieve those goals. Similarly, expanding on a decade-long relationship managing PR for Eli Lilly’s Prozac, the firm developed communications around Lilly’s entry to the depression marketplace with Cymbalta, developing a graphic novel following its protagonist through depression diagnosis, treatment and recovery.
The firm’s offerings include strategic, content development, professional and advocacy relations, media relations and interactive communications services, all fueled by applying in-depth industry and category knowledge; proprietary methods; creativity that comes from experienced, committed team members diverse in their professional, philosophical and cultural backgrounds; and the latest technology. The approach is designed to connect patients to brands, build supportive treatment practices and create a healthy environment for communicating with a sometimes skeptical public.
Richard Chamberlain, president, is a 25-year veteran of the healthcare sector who founded Chamberlain Communications in 1993, after working for the Society of Nuclear Medicine, Pfizer, Hill & Knowlton and Makovsky & Company. He is joined at the helm of the 35-person shop by Ovidio Torres, managing partner, and former senior managing director of the U.S. health practice at H&K; and Deborah Cohen, managing partner, who was formerly a manager with Sandler Public Relations.
Last year was the best year in the firm’s history, driven by significant new business from Pfizer, Sigma-Tau Pharmaceuticals and the Cardiovascular Research Foundation. The firm also expanded its work with Novartis to include ophthalmics, and with Eli Lilly to include corporate and internal communications.